DUBLIN – Verona Pharma plc raised $200 million in a combined private placement and share subscription, which ensures the London-based firm has the funds in place to proceed with a phase III program for its lead drug candidate, ensifentrine, as maintenance therapy in chronic obstructive pulmonary disease (COPD). It’s solid evidence that the company’s decision to bring in a new senior management team earlier this year is working. CEO David Zaccardelli and Chief Financial Officer Mark Hahn joined up in February, not long after they had led specialty pharma firm Dova Pharmaceuticals Inc. to a buyout deal with Stockholm-based Swedish Orphan Biovitrum AB, worth up to $915 million.